胰高血糖素样肽-1受体激动剂治疗代谢相关脂肪性肝炎的临床研究进展  

Clinical progress of glucagon-like peptide-1 receptor agonists in the treatment of metabolically associated steatohepatitis

作　　者：曾艳艳 兰志龙 李英博 姜山 倪娜 王俊龙 ZENG Yanyan;LAN Zhilong;LI Yingbo;JIANG Shan;NI Na;WANG Junlong(Clinical Research Center,China State Institute of Pharmaceutical Industry,Shanghai 200437,China;Shanghai InnoClinic Pharmaceutical Development Co,Ltd.,Shanghai 200437,China)

机构地区：[1]中国医药工业研究总院临床研究中心,上海200437 [2]上海益临思医药开发有限公司,上海200437

出　　处：《世界临床药物》2025年第2期130-137,共8页World Clinical Drug

摘　　要：代谢相关脂肪性肝炎(metabolic associated steatohepatitis,MASH),原名为非酒精性脂肪性肝炎。若不加以控制,其可导致肝硬化及肝癌的发生。随着学科不断发展,MASH的诊断和治疗均有很大进步,但由于其复杂的作用机制,不少临床试验即使进入Ⅲ期也以失败告终。该文从MASH的代谢障碍为考虑点,汇总其靶向代谢的胰高血糖素肽-1受体与其他肠促胰岛素信号通路的双重/三重受体激动剂,为更好地开发MASH治疗及设计相关临床试验提供一定参考。Metabolic associated steatohepatitis(MASH),formerly known as non-alcoholic steatohepatitis.If the disease is not controlled,it can lead to cirrhosis and liver cancer.With the continuous development of the discipline,the diagnosis and treatment of MASH have made great progress.However,because of its complex mechanism of action,many clinical trials have failed even after entering phase Ⅲ.This aritcle focused on the metabolic disorder of MASH,and summarized the double/triple receptor agonists targeting the metabolism of glucagon peptide-1 receptor and other incretin signaling pathways,so as to provide certain references for the better development of MASH treatment and the design of related clinical trials.

关 键 词：胰高血糖素样肽-1 胰高血糖素样肽-1受体激动剂 代谢相关脂肪性肝炎 非酒精性脂肪性肝炎 代谢相关脂肪性肝病 非酒精性脂肪性肝病 

分 类 号：R575.5[医药卫生—消化系统]